Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856160 | 0.90 | ADRB2 (0.38) | ADRB2ADRB1ADRB3ALDH1A1FLT3 | |
| SCHEMBL2858288 | 0.89 | FLT3 (0.43) | ADRB2ADRB1ADRB3ALDH1A1FLT3 | |
| SCHEMBL2864983 | 0.88 | ADRB2 (0.36) | ADRB2ADRB1ADRB3ALDH1A1KDM4E | |
| SCHEMBL2865399 | 0.87 | VNN1 (0.36) | ADRB2ADRB1ADRB3ALDH1A1FLT3 | |
| SCHEMBL2861694 | 0.86 | KDM4E (0.45) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2857059 | 0.86 | KDM4E (0.44) | ALDH1A1FLT3KDM4ENPC1RAB9A | |
| SCHEMBL6032268 | 0.85 | MAPT (0.49) | ADRB2ADRB1ADRB3ALDH1A1FLT3 | |
| SCHEMBL2861148 | 0.85 | KDM4E (0.40) | ADRB2ADRB1ADRB3ALDH1A1FLT3 | |
| SCHEMBL2857454 | 0.85 | KDM4E (0.43) | ADRB2ADRB1ADRB3ALDH1A1FLT3 | |
| SCHEMBL2866520 | 0.84 | KDM4E (0.39) | ADRB2ADRB1ADRB3ALDH1A1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642880-B1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7767693-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-7538224-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070032532-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1642880-A1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032532-A1 | Hsp90 family protein inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | ADRB2 3046/4885ADRB1 2066/4885ADRB3 2617/4885 |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | ADRB2 3046/4885ADRB1 2066/4885ADRB3 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.